Login to Your Account

Tivantinib Misses Again

Midstage Colorectal Cancer Data Dent ArQule's Shares

By Jennifer Boggs
Managing Editor

Friday, January 11, 2013
Three months after its shares were clobbered on disappointing survival data in non-small-cell lung cancer (NSCLC), ArQule Inc.'s stock sank again, after tivantinib, its MET inhibitor, missed primary and secondary endpoints in a Phase II trial in second-line colorectal cancer (CRC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription